Patents Examined by Jennifer Graser
  • Bacteriophage preparations and methods of use thereof
    Patent number: 9404089
    Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: August 2, 2016
    Assignees: Zoctis Services LLC, Intrlytix Inc.
    Inventors: Jeremy Mathers, Alexander Sulakvelidze
  • Gram-positive bacteria specific binding compounds
    Patent number: 9399673
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 26, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Combinations comprising a fungicidal strain and an active compound
    Patent number: 9392797
    Abstract: Fungicidal mixtures, comprising 1) a fungicidal strain (I) selected from a) the Bacillus substilis strain with NRRL Accession No. B-21661, and b) the Bacillus pumilus strain with NRRL Accession No. B-30087, or a mutant of these strains having all the identifying characteristics of the respective strain, or a metabolite produced by the respective strain that exhibits activity against plant pathogenic fungi, and 2) at least one chemical compound (II), selected from the active compound groups A) to F): A) azoles; B) strobilurins; C) carboxamides; D) heterocyclic compounds; E) carbamates; F) other fungicides; in a synergistically effective amount, methods for controlling harmful fungi using compositions of components 1) and 2), the use of a component 1) with a component 2) for preparing such compositions, and also fungicidal agents and seed comprising such compositions.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: July 19, 2016
    Assignee: Bayer CropScience LP
    Inventors: Ulrich Schoefl, Maria Scherer, Egon Haden
  • Polyvalent chimeric OspC vaccinogen and diagnostic antigen
    Patent number: 9376472
    Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: June 28, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Richard T. Marconi, Christopher Earnhart
  • Deimmunized serum-binding domains and their use in extending serum half-life
    Patent number: 9376495
    Abstract: The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: June 28, 2016
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Bhaswati Barat, Ling Huang, Leslie S. Johnson
  • Methods and devices for detecting methicillin resistant
    Patent number: 9372191
    Abstract: Provided are methods and devices for detecting methicillin-resistant Staphylcoccus aureus.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: June 21, 2016
    Assignee: Alere Switzerland GmbH
    Inventors: Dorothy Joanis, Myron Whipkey, Erin Hayes, Steven Muszynski, Alan H. Davis, Kristin Gordon, Roger N. Piasio, Norman James Moore
  • Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines
    Patent number: 9364533
    Abstract: The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen. The invention further relates to kits comprising (i) a first composition comprising a Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and a polyanionic polymer, and (ii) a second composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: June 14, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Nathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
  • Immunogenic proteins of
    Patent number: 9366671
    Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: June 14, 2016
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Yung-Fu Chang, Raghavan U. M. Palaniappan
  • Antibody specific to , therapeutic method and detection method using same
    Patent number: 9353189
    Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 31, 2016
    Inventor: William R Church
  • Proteins with repetitive Bacterial-Ig-like (Big) domains present in species
    Patent number: 9346858
    Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 24, 2016
    Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZ
    Inventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
  • Treatment of streptococcal infections
    Patent number: 9314518
    Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: April 19, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Denoel, Philippe Vincent Hermand, Steve Labbe, Jan Poolman, Stephane Rioux
  • Selection of RNA-aptamers as anti-malaria agents
    Patent number: 9309516
    Abstract: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1?, DBL1?, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 12, 2016
    Assignee: APTAHEM AB
    Inventors: Johan Lindh, Tina Persson
  • Selection of RNA-aptamers as anti-malaria agents
    Patent number: 9309517
    Abstract: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1?, DBL1?, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 12, 2016
    Assignee: APTAHEM AB
    Inventors: Johan Lindh, Tina Persson
  • D-amino acid derivative-modified peptidoglycan and methods of use thereof
    Patent number: 9303068
    Abstract: The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: April 5, 2016
    Assignee: The Regents of the University of California
    Inventors: Carolyn R. Bertozzi, Mary Sloan Siegrist Palmore, John C. Jewett, Chelsea G. Gordon, Peyton Shieh
  • Multi-coated lactic acid bacteria and preparing method thereof
    Patent number: 9296987
    Abstract: The present invention relates to multi-coated lactic acid bacteria coated with a multi-coating layer forming bacterial clusters and including protein, polysaccharide, and edible oil/fat component, and a preparing method thereof. The multi-coated lactic acid bacteria according to the present invention may achieve an improved acid resistance, a bile resistance, and an accelerated test stability, may have a low moisture content to be particularly stable against a moisture variation, and thus may be appropriately used to prepare various products including lactic acid bacteria.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: March 29, 2016
    Assignee: Cell Biotech Co., Ltd.
    Inventor: Myung Jun Chung
  • Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety
    Patent number: 9297015
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: March 29, 2016
    Assignees: Arizona Board of Regents for and on behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Strain of
    Patent number: 9297049
    Abstract: The invention relates to a new strain of Lactobacillus mucosae which is able to decrease intestinal barrier permeability. This strain is useful in particular for alleviating intestinal barrier dysfunctions.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: March 29, 2016
    Assignee: Compagnie Gervais Danone
    Inventors: Tamara Smokvina, Marie-Christine Degivry
  • Immunogenic composition
    Patent number: 9290565
    Abstract: The present invention relates to fusion proteins comprising fragments of toxin A and toxin B from Clostridium difficile, such as wherein the first fragment and the second fragment are adjacent to one another and wherein the first repeat portion and the second repeat portion have sequence similarity to one another.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: March 22, 2016
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventor: Cindy Castado
  • Therapeutic application of C-terminal peptide
    Patent number: 9289485
    Abstract: A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcus.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: March 22, 2016
    Inventors: Luiza Guilherme Guglielmi, Jorge Elias Kalil Filho
  • Proteins used for the diagnosis of lyme borreliosis
    Patent number: 9290548
    Abstract: A nucleic acid encoding a chimeric protein, the chimeric protein including (i) at least one amino acid sequence having at least 50% sequence identity with any of the amino acid sequences selected from the group consisting of SEQ ID NOS: 1-5, and (ii) at least one amino acid sequence having at least 80% sequence identity with any of the amino acid sequences selected from the group consisting of SEQ ID NOS: 6-8. The chimeric protein includes at least one amino acid sequence of (i) and at least one amino acid sequence of (ii) that are from different Borrelia strains or species.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 22, 2016
    Assignee: BIOMERIEUX
    Inventors: Lionel Levet, Odile Mejan-Letourneur